Critical role of c-Jun N-terminal protein kinase activation in troglitazone-induced apoptosis of human HepG2 hepatoma cells

Molecular Pharmacology

Volumn 63, Issue 2, 2003, Pages 401-408

  Bae, Myung Ae ^a   Song, Byoung J ^a  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ARGININE; COMPLEMENTARY DNA; CYTOCHROME C; DNA FRAGMENT; HOE 33342; LYSINE; MITOGEN ACTIVATED PROTEIN KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BID; PROTEIN KINASE INHIBITOR; ROSIGLITAZONE; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; TROGLITAZONE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL DAMAGE; CELL STRAIN HEPG2; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA TRANSFECTION; DRUG ANTAGONISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HEPATOMA CELL; HUMAN; HUMAN CELL; LIVER TOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN DEGRADATION; SIGNAL TRANSDUCTION;

ANTHRACENES; ANTINEOPLASTIC AGENTS; APOPTOSIS; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; CARCINOMA, HEPATOCELLULAR; CARRIER PROTEINS; CHROMANS; CYCLOHEXIMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME ACTIVATION; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MITOGEN-ACTIVATED PROTEIN KINASES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; SIGNAL TRANSDUCTION; THIAZOLES; THIAZOLIDINEDIONES; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0037308871     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.63.2.401     Document Type: Article

References (39)

1. 2-terminal protein kinase-related cell death pathway. Mol Pharmacol 60:847-856.
2. Bai J and Cederbaum AI (2000) Overexpression of catalase in the mitochondrial or cytosolic compartment increases sensitivity of HepG2 cells to tumor necrosis factor-alpha-induced apoptosis. J Biol Chem 275:19241-19249.
3. Beales PE, Liddi R, Giorgini AE, Signore A, Procaccini E, Batchelor K, and Pozzilli P (1998) Troglitazone prevents insulin dependent diabetes in the non-obese diabetic mouse. Eur J Pharmacol 357:221-225.
4. Bennett BL, Sasaki DT, Murray BW, O'Leary EC, Sakata ST, Xu W, Leisten JC, Motiwala A, Pierce S, Satoh Y, et al. (2001) SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci USA 98:13681-13686.
5. Chao DT and Korsmeyer SJ (1998) BCL-2 family: Regulators of cell death. Annu Rev Immunol 16:395-419.
6. Chen Y-R, Wang X, Templeton D, Davis RJ, and Tan T-H (1996) The role of c-Jun N-terminal kinase (JNK) in apoptosis induced by ultraviolet C and gamma radiation. Duration of JNK activation may determine cell death and proliferation. J Biol Chem 271:31929-31936.
7. Chinetti G, Griglio S, Antonucci M, Torra IP, Delerive P, Majd Z, Fruchart JC, Chapman J, Najib J, and Staels B (1998) Activation of proliferator-activated receptors α and γ induces apoptosis of human monocyte-derived macrophages. J Biol Chem 273:25573-25580.
8. Daily D, Vlamis-Gardikas A, Offen D, Mittelman L, Melamed E, Holmgren A, and Barzilai A (2001) Glutaredoxin protects cerebellar granule neurons from dopamine-induced apoptosis by dual activation of the ras-phosphoinositide 3-kinase and Jun N-terminal kinase pathways. J Biol Chem 276:21618-21626.
9. Day C (1999) Thiazolidinediones: a new class of antidiabetic drugs. Diabet Med 16:179-192.
10. Engedal N and Saatcioglu F (2001) Ceramide-induced cell death in the prostate cancer cell line LNCaP has both necrotic and apoptotic features. Prostate 46:289-297.
11. Gouni-Berthold I, Berthold HK, Weber AA, Ko Y, Seul C, Vetter H, and Sachinidis A (2001) Troglitazone and rosiglitazone induce apoptosis of vascular smooth muscle cells through an extracellular signal-regulated kinase-independent pathway. Naunyn-Schmiedeberg's Arch Pharmacol 363:215-221.
12. Hirase N, Yanase T, Mu Y, Muta K, Umemura T, Takayanagi R, and Nawata H (1999) Thiazolidinedione induces apoptosis and monocytic differentiation in the promyelocytic leukemia cell line HL60. Oncology 57:17-26.
13. Inanami O, Ohta T Ito S and Kuwabara M (1999) Elevation of intracellular calcium ions is essential for the H202-induced activation of SAPK/JNK but not for that of p38 and ERK in Chinese hamster V79 cells. Antioxid Redox Signal 1:501-508.
14. Karin M (1995) The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Chem 270:16483-16486.
15. Kassahun K, Pearson PG, Tang W, McIntosh I, Leung K, Elmore C, Dean D, Wang R, Doss G, and Bailliem TA (2001) Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission. Chem Res Toxicol 14:62-70.
16. 2, a ligand for peroxisome proliferator-activated receptor-γ, induces apoptosis in JEG3 Choriocarcinoma cells. Biochem Biophys Res Commun 262:579-585.
17. Kitamura S, Miyazaki Y, Shinomura Y, Kondo S, Kanayama S, and Matsuzawa Y (1999) Peroxisome proliferator-activated receptor gamma induces growth arrest and differentiation markers of human colon cancer cells. Jpn J Cancer Res 90:75-80.
18. Kostrubsky VE, Sinclair JF, Ramachandran V, Venkataramanan R, Wen YH, Kindt E, Galchev V, Rose K, Sinz M, and Strom SC (2000) The role of conjugation in hepatotoxicity of Troglitazone in human and porcine hepatocyte cultures. Drug Metab Dispos 28:1192-1197.
19. Lebovitz HE, Kreider M, and Freed MI (2002) Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Diabet Care 25:815-821.
20. Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, McNulty D, Blumenthal MJ, Heys JR, Landvatter SW, et al. (1994) A protein kinase involved in the regulation of inflammatory cytokine biosyhthesis. Nature (Lond) 372:739-746.
21. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, and Kliewer SA (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPARγ). J Biol Chem 270:12953-12956.
22. Le-Niculescu H, Bonfoco E, Kasuya Y, Claret FX, Green DR, and Karin M (1999) Withdrawal of survival factors results in activation of the JNK pathway in neuronal cells leading to Fas ligand induction and cell death. Mol Cell Biol 19:751-763.
23. Li H, Zhu H, Xu CJ, and Yuan J (1998) Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94:491-501.
24. Mahler RJ and Adler ML (1999) Clinical review 102: type 2 diabetes mellitus: update on diagnosis, pathophysiology and treatment. J Clin Endocrinol Metab 84:1165-1171.
25. Maroney AC, Finn JP, Bozyczko-Coyne D, O'Kane TM, Neff NT, Tolkovsky AM, Park DS, Yan CY, Troy CM, and Greene LA (1999) CEP-1347 (KT7515), an inhibitor of JNK activation, rescues sympathetic neurons and neuronally differentiated PC 12 cells from death evoked by three distinct insults. J Neurochem 73:1901-1912.
26. Ohtani KI, Shimizu H, Sato N, and Mori M (1998) Troglitazone (CS-045) inhibits β-cell proliferation rate following stimulation of insulin secretion in HIT-T 15 cells. Endocrinology 139:172-178.
27. Okura T, Nakamura M, Takata Y, Watanabe S, Kitami Y, and Hiwada K (2000) Troglitazone induces apoptosis via the p53 and Gadd45 pathway in vascular smooth muscle cells. Eur J Pharmacol 407:227-235.
28. Ramachandran V, Kostrubsky VE, Kamoroski EJ, Zhang S, Dorko K, Esplen JE, Strom SC, and Venkataramanan R (1999) Troglitazone increases cytochrome P-450 3A protein and activity in primary cultures of human hepatocytes. Drug Metab Dispos 27:1194-1199.
29. Slee EA, Keogh SA, and Martin SJ (2000) Cleavage of BID during cytotoxic drug and UV radiation-induced apoptosis occurs downstream of the point of Bcl-2 action and is catalysed by caspase-3: a potential feedback loop for amplification of apoptosisassociated mitochondrial cytochrome c release. Cell Death Differ 7:556-565.
30. Soh Y, Jeong KS, Lee IJ, Bae MA, Kim YC, and Song BJ (2000) Selective activation of the c-Jun N-terminal protein kinase pathway during 4-hydroxynonenal-induced apoptosis of PC12 cells. Mol Pharmacol 58:535-541.
31. Tafani M, Karpinich NO, Hurster KA, Pastorino JG, Schneider T, Russo MA, and Farber JL (2002) Cytochrome c release upon Fas receptor activation depends on translocation of full-length bid and the induction of the mitochondrial permeability transition. J Biol Chem 277:10073-10082.
32. Tournier C, Hess P, Yang DD, Xu J, Turner TK, Nimnual A, Bar-Sagi D, Jones SN, Flavell RA, and Davis RJ (2000) Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science (Wash DC) 288:870-874.
33. Toyoda M, Takagi H, Horiguchi N, Kakizaki S, Sato K, Takayama H, and Mori M (2002) A ligand for peroxisome proliferator activated inhibits cell growth and induces apoptosis in human liver cancer cells. Gut 50:563-567.
34. Toyoda Y, Tsuchida A, Iwami E, and Miwa I (2001) Toxic effect of troglitazone on cultured rat hepatocytes. Life Sci 68:1867-1876.
35. Watkins P and Whitcomb RW (1998) Hepatic dysfunction associated with troglitazone. N Engl J Med 338:916-917.
36. Wilson TM, Cobb JE, Cowan DJ, Wiethe RW, Correa ID, Prakash SR, Beck KD, Moore LB, Kliewer SA, and Lehmann JM (1996) The structure-activity relationship between peroxisome proliferator-activated receptor agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem 39:665-668.
37. Xia Z, Dickens M, Raingeaud J, Davis RJ, and Greenberg ME (1995) Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science (Wash DC) 270:1326-1331.
38. Yamazaki H, Shibata A, Suzuki M, Nakajima M, Shimada N, Guengerich FP, and Yokoi T (1999) Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P-450 2C8 and P-450 3A4 in human liver microsomes. Drug Metab Dispos 27:1260-1266.
39. Yin X-M (2000) Bid, a critical mediator for apoptosis induced by the activation of Fas/TNF-R1 death receptors in hepatocytes. J Mol Med 78:203-211.